Cognate BioServices expands manufacturing in U.S., Europe
Contract development and manufacturing organization Cognate BioServices plans to expand cell and gene therapy manufacturing capacity, laboratory space, warehousing capabilities, and to increase office support at its facilities in the U.S. and Europe.
RoosterBio, Sartorius partner on cell and gene therapy manufacturing
RoosterBio and Sartorius have signed a strategic collaboration to advance the scale-up of human mesenchymal stem/stromal cells manufacturing for regenerative medicines.
Development 'cookbooks' could speed up gene therapy
Great strides have been made in the development of gene editing tools in the past decade, but translating the technology into real therapies to treat patients has taken longer than expected. How to accelerate this process was the subject of a panel discussion on January 13 at the Biotech Showcase virtual event.  Discuss
Fujifilm secures funding, signs lease for new research/manufacturing center
Fujifilm Diosynth Biotechnologies has announced $76 million in financing for the Center for Advanced Biological Innovation and Manufacturing and that a lease for a site in the Boston area has been signed.
Bone Therapeutics, Rigenerand partner on cell therapy process development
Bone Therapeutics and Rigenerand have formed a cell therapy process development partnership.
Lentigen to manufacture vector for Oncternal
Oncternal Therapeutics announced an agreement with Lentigen Technology, a subsidiary of Miltenyi Biotec, to manufacture lentiviral vectors for Octernal's investigational receptor tyrosine kinase-like orphan receptor 1-targeting chimeric antigen receptor T-cell therapy program.
KSQ Therapeutics, Takeda to develop novel cancer immunotherapies
KSQ Therapeutics has entered into a broad strategic collaboration with Takeda Pharmaceutical to research, develop, and commercialize novel immune-based therapies for cancer.
Cytovia licenses CAR NK tech to NCI
Cytovia Therapeutics has signed a licensing agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to apply its gene-edited induced pluripotent stem cell-derived technology to develop glypican-3 (GPC3) chimeric antigen receptor (CAR) natural killer (NK) cell therapeutics.
Bayer media day focuses on cell, gene, oncology channels
Bayer highlighted its focus on cell, gene, and oncology pipelines during its virtual Pharma Media Day in Germany.
Taysha, UTSW start fund to speed up CNS gene therapies
Taysha Gene Therapies and the University of Texas Southwestern Medical Center (UTSW) have launched a fund to accelerate the development of adeno-associated virus gene therapies for monogenic diseases of the central nervous system (CNS).
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter